These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 26567881)
1. Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies. Cao L; Fan L; Xu W; Li JY Curr Cancer Drug Targets; 2015; 15(9):769-80. PubMed ID: 26567881 [TBL] [Abstract][Full Text] [Related]
2. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer. Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313 [TBL] [Abstract][Full Text] [Related]
3. MDM4 is a key therapeutic target in cutaneous melanoma. Gembarska A; Luciani F; Fedele C; Russell EA; Dewaele M; Villar S; Zwolinska A; Haupt S; de Lange J; Yip D; Goydos J; Haigh JJ; Haupt Y; Larue L; Jochemsen A; Shi H; Moriceau G; Lo RS; Ghanem G; Shackleton M; Bernal F; Marine JC Nat Med; 2012 Aug; 18(8):1239-47. PubMed ID: 22820643 [TBL] [Abstract][Full Text] [Related]
4. Mdm4 loss in mice expressing a p53 hypomorph alters tumor spectrum without improving survival. Fang M; Simeonova I; Bardot B; Lejour V; Jaber S; Bouarich-Bourimi R; Morin A; Toledo F Oncogene; 2014 Mar; 33(10):1336-9. PubMed ID: 23474762 [TBL] [Abstract][Full Text] [Related]
5. Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Xiong S; Pant V; Suh YA; Van Pelt CS; Wang Y; Valentin-Vega YA; Post SM; Lozano G Cancer Res; 2010 Sep; 70(18):7148-54. PubMed ID: 20736370 [TBL] [Abstract][Full Text] [Related]
6. Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity. Bardot B; Bouarich-Bourimi R; Leemput J; Lejour V; Hamon A; Plancke L; Jochemsen AG; Simeonova I; Fang M; Toledo F Oncogene; 2015 May; 34(22):2943-8. PubMed ID: 25088193 [TBL] [Abstract][Full Text] [Related]
7. MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. Mancini F; Di Conza G; Pellegrino M; Rinaldo C; Prodosmo A; Giglio S; D'Agnano I; Florenzano F; Felicioni L; Buttitta F; Marchetti A; Sacchi A; Pontecorvi A; Soddu S; Moretti F EMBO J; 2009 Jul; 28(13):1926-39. PubMed ID: 19521340 [TBL] [Abstract][Full Text] [Related]
8. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Chandler DS; Singh RK; Caldwell LC; Bitler JL; Lozano G Cancer Res; 2006 Oct; 66(19):9502-8. PubMed ID: 17018606 [TBL] [Abstract][Full Text] [Related]
9. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Marine JC; Francoz S; Maetens M; Wahl G; Toledo F; Lozano G Cell Death Differ; 2006 Jun; 13(6):927-34. PubMed ID: 16543935 [No Abstract] [Full Text] [Related]
10. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333 [TBL] [Abstract][Full Text] [Related]
11. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Toledo F; Wahl GM Nat Rev Cancer; 2006 Dec; 6(12):909-23. PubMed ID: 17128209 [TBL] [Abstract][Full Text] [Related]
12. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Xiong S; Van Pelt CS; Elizondo-Fraire AC; Liu G; Lozano G Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3226-31. PubMed ID: 16492743 [TBL] [Abstract][Full Text] [Related]
13. MDM4 expression in fibrolamellar hepatocellular carcinoma. Karki A; Putra J; Kim SS; Laquaglia MJ; Perez-Atayde AR; Sadri-Vakili G; Vakili K Oncol Rep; 2019 Oct; 42(4):1487-1496. PubMed ID: 31322272 [TBL] [Abstract][Full Text] [Related]
14. Polo-like kinase and its inhibitors: Ready for the match to start? Palmisiano ND; Kasner MT Am J Hematol; 2015 Nov; 90(11):1071-6. PubMed ID: 26294255 [TBL] [Abstract][Full Text] [Related]
15. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Terzian T; Wang Y; Van Pelt CS; Box NF; Travis EL; Lozano G Mol Cell Biol; 2007 Aug; 27(15):5479-85. PubMed ID: 17526734 [TBL] [Abstract][Full Text] [Related]
16. MDM4 is a rational target for treating breast cancers with mutant p53. Miranda PJ; Buckley D; Raghu D; Pang JB; Takano EA; Vijayakumaran R; Teunisse AF; Posner A; Procter T; Herold MJ; Gamell C; Marine JC; Fox SB; Jochemsen A; Haupt S; Haupt Y J Pathol; 2017 Apr; 241(5):661-670. PubMed ID: 28097652 [TBL] [Abstract][Full Text] [Related]
17. p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis. Tashakori M; Zhang Y; Xiong S; You MJ; Lozano G Mol Cancer Res; 2016 Jan; 14(1):56-65. PubMed ID: 26527653 [TBL] [Abstract][Full Text] [Related]
18. Mdm4 loss in the intestinal epithelium leads to compartmentalized cell death but no tissue abnormalities. Valentin-Vega YA; Box N; Terzian T; Lozano G Differentiation; 2009 Jun; 77(5):442-9. PubMed ID: 19371999 [TBL] [Abstract][Full Text] [Related]
19. Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Grier JD; Xiong S; Elizondo-Fraire AC; Parant JM; Lozano G Mol Cell Biol; 2006 Jan; 26(1):192-8. PubMed ID: 16354690 [TBL] [Abstract][Full Text] [Related]
20. MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response. Mancini F; Pieroni L; Monteleone V; Lucà R; Fici L; Luca E; Urbani A; Xiong S; Soddu S; Masetti R; Lozano G; Pontecorvi A; Moretti F Oncogene; 2016 Jan; 35(2):228-40. PubMed ID: 25961923 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]